Skip to main content

Table 3 SCD-plus criteria and the risk of preclinical AD in individuals with available amyloid status (n = 114)

From: Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results

Predictor Data availability (n) Prevalence of SCD-plus criteriaa Risk of preclinical ADb
in group with known amyloid status (n = 114) Preclinical AD (n = 28) Amyloid negative (n = 86) Univariate model Multivariate stepwise model
Memory specific decline 94 13 (59%) 37 (51%) 1.4 (0.5–3.6)
Onset < 5 years 111 12 (46%) 43 (51%) 0.8 (0.3–2.0)
Age ≥ 60 years 114 26 (93%) 54 (63%) 7.7 (1.7–34.6) 3.8 (1.7–20.4)
Experience of worse performance than others 90 13 (65%) 44 (63%) 1.1 (0.4–3.1)
Informant reports decline 97 15 (60%) 32 (44%) 1.9 (0.7–4.7)
APOE e4 carriership 110 17 (65%) 23 (27%) 5.0 (2.0–12.8) 6.2 (1.7–22.2)
  1. AD Alzheimer’s disease, APOE apolipoprotein E (genotype), SCD subjective cognitive decline
  2. aPrevalence of each SCD-plus criterion in individuals with and without preclinical AD, presented as n (%), within cases with amyloid status available (n = 114)
  3. bRisk of preclinical AD separately (univariate models) for each SCD-plus criterion and independent predictors of preclinical AD in a multivariate stepwise model in SCIENCe participants with available amyloid status (n = 114), presented as odds ratio (95% confidence interval)